TABORSKY, Milos, Tomas SKALA, Renata AIGLOVA, Marian FEDORCO, Josef KAUTZNER, Tomas JANDIK, Vlastimil VANCURA, Ales LINHART, Martin VALEK, Miloslav NOVAK, Petr KALA, Rostislav POLASEK, Tomas ROUBICEK, Alexandr SCHEE, Gerhard HINDRICKS, Nikolaos DAGRES, Robert HATALAJ a Jiří JARKOVSKÝ. Cardiac Resynchronization and Defibrillator Therapy (CRT-D) or CRT Alone (CRT-P) in patients with dilated cardiomyopathy and heart failure without late gadolinium enhancement (LGE) cardiac magnetic resonance imaging (CMRI) high-risk markers- CRT-REALITY study - Study design and rationale. Biomedical Papers, Olomouc: Palacky University. Olomouc: Palacky University, 2022, roč. 166, č. 2, s. 173-179. ISSN 1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2021.015.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Cardiac Resynchronization and Defibrillator Therapy (CRT-D) or CRT Alone (CRT-P) in patients with dilated cardiomyopathy and heart failure without late gadolinium enhancement (LGE) cardiac magnetic resonance imaging (CMRI) high-risk markers- CRT-REALITY study - Study design and rationale
Autoři TABORSKY, Milos (203 Česká republika), Tomas SKALA (203 Česká republika), Renata AIGLOVA (203 Česká republika), Marian FEDORCO (203 Česká republika), Josef KAUTZNER (203 Česká republika), Tomas JANDIK (203 Česká republika), Vlastimil VANCURA (203 Česká republika), Ales LINHART, Martin VALEK (203 Česká republika), Miloslav NOVAK (203 Česká republika), Petr KALA, Rostislav POLASEK (203 Česká republika), Tomas ROUBICEK (203 Česká republika), Alexandr SCHEE, Gerhard HINDRICKS, Nikolaos DAGRES, Robert HATALAJ a Jiří JARKOVSKÝ (203 Česká republika, domácí).
Vydání Biomedical Papers, Olomouc: Palacky University, Olomouc, Palacky University, 2022, 1213-8118.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Česká republika
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 0.900
Kód RIV RIV/00216224:14110/22:00125206
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.5507/bp.2021.015
UT WoS 000731340300001
Klíčová slova anglicky non-ischemic cardiomyopathy; heart failure; implantable cardioverter-defibrillator; cardiac resynchronization therapy; magnetic resonance imaging; late gadolinium enhancement; randomized controlled trial
Štítky 14119612, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 20. 7. 2022 09:03.
Anotace
Background. Primary preventive implantation of implantable defibrillator (ICD) is according to current guidelines indicated in patients with heart failure NYHA (New York Heart Association) class II/III and LVEF <35%. Thanks to ad-vances in heart failure pharmacotherapy, a decrease in mortality could render a benefit of ICD insufficient to justify its implantation in some patients. Methods. Study design: multicenter, prospective, randomized, controlled trial evaluating the benefit of implantation of Cardiac Resynchronization and Defibrillator Therapy (CRT-D) or CRT Alone (CRT-P) in non-ischemic patients with reduced left ventricle ejection fraction (LVEF) and optimal pharmacotherapy without significant mid-wall myocardial fibrosis detected by cardiac magnetic resonance (CMR). The primary end-point: Re-hospitalization for heart failure, ventricular tachycardia, major adverse cardiac events (MACE). The secondary end-points: Sudden cardiac death, cardiovascular death, resuscitated cardiac arrest or sustained ventricular tachycardia, device-related complications, and change in quality of life. Course of the study: After a pharmacotherapy is optimized and significant mid-wall myocardial fibrosis excluded, patients will be randomized 1:1 to CRT-P or CRT-D implantation. Discussion. If our hypothesis is confirmed, this could provide evidence for the management of these patients with a significant impact on common daily praxis and health care expenditures. Trial registration. ClinicalTrials.gov, NCT04139460
VytisknoutZobrazeno: 25. 4. 2024 02:33